Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, M.
Right arrow Articles by Brooks, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, M.
Right arrow Articles by Brooks, M. N.
[Cancer Research 65, 6159-6166, July 15, 2005]
© 2005 American Association for Cancer Research

Cell and Tumor Biology

The Novel Gene EG-1 Stimulates Cellular Proliferation

Ming Lu1, Liping Zhang1, Raymond Scott Maul1, Maryam R. Sartippour1, Andrew Norris1, Julian Whitelegge3, Jian Yu Rao2 and Mai N. Brooks1

Department of 1 Surgery, Division of Oncology, and 2 Department of Pathology, School of Medicine, and 3 Department of Chemistry and Biochemistry, University of California at Los Angeles, Los Angeles, California

Requests for reprints: Mai N. Brooks, University of California at Los Angeles, Box 951782, Los Angeles, CA 90095. Phone: 310-206-2215; Fax: 310-825-7575; E-mail: maibrooks{at}mednet.ucla.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We recently discovered a novel gene and named it endothelial-derived gene 1 (EG-1). Previously, we have shown that the expression of EG-1 is significantly elevated in the epithelial cells of breast cancer, colorectal cancer, and prostate cancer. Here, we report that EG-1 can stimulate cellular proliferation. Transfection experiments which overexpressed the full-length EG-1 gene in human embryonic kidney HEK-293 cells or human breast cancer cell lines resulted in significantly increased in vitro proliferation, in comparison with transfection with empty vectors. On the other hand, small interfering RNA cotransfection resulted in inhibition of proliferation. S.c. xenograft assays were carried out in a severe combined immunodeficient mouse model. We found that injection of high EG-1 expressing HEK-293 clones resulted in significantly larger tumors, in comparison with clones carrying the empty vectors. To further clarify the function of this gene, we investigated its interaction with Src and members of the mitogen-activated protein kinase (MAPK) family. Immunoprecipitation with anti-Src antibody, followed by immunoblotting with anti–EG-1 antibody, showed an association between these two molecules. Overexpression of EG-1 was correlated with activation of the following kinases: extracellular signal-regulated kinases 1 and 2, c-jun-NH2-kinase, and p38. These observations collectively support the hypothesis that the novel gene EG-1 is a positive stimulator of cellular proliferation, and may possibly be involved in signaling pathways involving Src and MAPK activation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Cancer is a major cause of morbidity and the second leading cause of death in the American population. Several major oncogenes and tumor suppressor genes have been identified to contribute to the neoplastic transformation of epithelial cells. These include src, p53, c-myc, ras, Rb (retinoblastoma), BRCA-1 and BRCA-2 (breast cancer susceptibility genes), Her-2, cyclin D1, and PTEN (phosphatase and tensin homologue; ref. 1). Other alterations in the cell, such as DNA methylation, contribute to the overall genetic instability, and abnormal maintenance of telomerases results in replicative immortality (2).

Another important biological phenomenon in the tumorigenic and metastatic phenotype involves the process of angiogenesis. Three decades of experimental evidence has shown that the growth and metastasis of solid tumors is dependent on their ability to initiate and sustain new capillary growth (i.e., angiogenesis; ref. 3). Multiple clinical observations in human cancer have added support to the hypothesis that tumors are angiogenesis dependent. The number of vessels in a tumor specimen correlates with the disease stage and can add prognostic value independent of other routinely used markers (4). Furthermore, the levels of various angiogenic factors in bodily fluids have been shown to correlate with prognosis in cancer patients (5–7). Many agents have been developed to inhibit tumor angiogenesis, and there have been reports of some encouraging results (8, 9).

Several researchers, including our laboratory, have investigated the difference between molecules of the proliferating tumor endothelium and those of the normal quiescent endothelium (10, 11). To closely mimic a tumor environment, we have attempted to identify endothelial gene products expressed in response to a mixture of growth factors found in tumor-conditioned media. Toward this goal, we used a subtraction hybridization method called suppression subtractive hybridization (12). In human umbilical vein endothelial cell populations exposed to conditioned media from human cancer cells (13) for 4 hours, we have isolated multiple clones (14, 15). One of these differentially expressed genes is endothelial-derived gene 1 (EG-1; ref. 16). In addition to its expected presence in blood vessels, EG-1 expression is significantly elevated in the epithelial cells of several cancers including breast, colorectal, and prostate cancer (17). In this article, we present in vitro and in vivo data which suggest that EG-1 stimulates cellular proliferation and may be involved in signaling pathways involving Src and mitogen-activated protein (MAP) kinase (MAPK) activation.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture. Human embryonic kidney HEK-293 cells and the human breast cancer cell lines MCF-7 and MDA-MB-231 were purchased from American Tissue Type Culture Collection (Rockville, MD). The cells were maintained in RPMI (Invitrogen, Carlsbad, CA) with 10% heat-inactivated FCS, 100,000 units/L penicillin, and 100 mg/L streptomycin at 37°C in 5% CO2.

Proliferation assay. The cells were plated onto 48-well culture plates at 10,000 cells/well and incubated at 37°C in 5% CO2 for 48 hours in DMEM with 10% FCS. On the third day, 1 µCi of [methyl-3H]thymidine (Amersham, Piscataway, NJ) was added to each well. Approximately 15 hours later, the plates were washed with PBS. The cells were fixed with trichloroacetic acid, washed with ethyl alcohol, and lysed with sodium hydroxide. After adding glacial acetic acid, the radioactivity of the cell lysates was counted in scintillation solution (ScintiVerse, Fisher, Pittsburgh, PA). The in vitro assays were done in triplicates. Certain experiments were carried out with MAPK inhibitors (PD98059, SB203580, and U0126) purchased from Calbiochem (La Jolla, CA). The cells were treated with 10 µmol/L of one of the above inhibitors for 24 hours before harvest.

Transfection. We used the pcDNA3.1D/V5-His-TOPO vectors (Invitrogen) to carry the full-length human EG-1 gene according to the instructions of the manufacturer. Empty vectors were used as negative controls. Specifically, standard calcium-phosphate DNA coprecipitation was used for obtaining stable transfectants. Individual clones were selected for Geneticin (Invitrogen) resistance over a period of several weeks. Expression of the EG-1 gene by individual clones was confirmed by Northern and Western blot analyses.

For transient transfection, we used the pcDNA3.1D/V5-His-TOPO and pShuttle-IRES-hrGFP-1 (Stratagene, La Jolla, CA) vectors to carry the full-length EG-1 gene. Empty vectors were used as negative controls. Liposomal reagents were used to transfect the pcDNA3.1D/V5-His-TOPO vectors into cells using the MBS Mammalian Transfection Kit according to the protocol of the manufacturer (Stratagene).

Small interfering RNA. EG-1 expression knockdown was achieved by transfecting a lentivirus vector expressing a small interfering RNA (siRNA) against EG-1, cis-linked with a green fluorescent protein expression cassette, into HEK-293 cells or breast cancer cells. The pCSUECG plasmid (U6-shRNA-EG1-CMV-GFP) was constructed by ligating the BamHI/EcoRI digests of pCSCG and the U6-shRNA-EG1 PCR product. The U6-shRNA-EG1 PCR was done using a hU6-containing plasmid at an annealing temperature of 60°C with the primers 5'-GGGGGATCCCAAGGTCGGGCAGGAAGAGGGCCTATTTCC-3'; for siRNA1, 5'-GGGGAATTCAAAAAGAAATTCGAACCGGTGTTGTCTCTTGAACAACACCGGTTCGAATTTCGGTGTTTCGTCCTTTCCACAAGATATATAAA-3'; for siRNA2, 5'-GGGGAATTCAAAAAGTTTCTGGATATTGCAAGATCTCTTGAATCTTGCAATATCCAGAAACGGTGTTTCGTCCTTTCCACAAGATATATAAA-3'; and for siRNA3, 5'-GGGGAATTCAAAAAGAGGATGTGTCAGAACTAATCTCTTGAATTAGTTCTGACACATCCTCGGTGTTTCGTCCTTTCCACAAGATATATAAA-3'.

Mouse tumor model. Severe combined immunodeficient (SCID) mice were bred in a pathogen-free colony at the University of California at Los Angeles School of Medicine. Eight- to ten-week-old female mice were housed four per cage, and fed ad libitum with sterilized food pellets and sterile water. We injected cells s.c. into the flank of the mice. We examined the effect of EG-1 on the tumorigenicity of HEK-293 cells. Wild-type, stably transfected empty vector or EG-1–overexpressing clones (4 x 107-5 x 107 cells) were injected s.c. into the flank of SCID mice. The tumor size was measured in three dimensions with calipers starting at day 7. The mice were observed for any change in behavior, appearance, or weight. At the end of the experiment, the mice were sacrificed by nitrogen gas environment. The primary tumor tissues were fixed in 10% formalin and converted into paraffin blocks.

Generation of antibodies. Polyclonal antibodies that recognize five different epitopes on human EG-1 were generated by Washington Biotechnology (Baltimore, MD). Briefly, different antigenic peptide fragments of human EG-1 were synthesized and used to immunize the rabbits. Preimmune and immune sera were harvested. Polyclonal antibodies were also affinity purified. For Western blot analysis, the secondary antibody used was horseradish peroxidase–conjugated goat anti-rabbit immunoglobulin G (IgG) from Jackson ImmunoResearch (West Grove, PA). The anti-FLAG M2 antibodies were obtained from Sigma (St. Louis, MO). The antibodies against MAPK and phospho-MAPK, c-jun-NH2-kinase (JNK) and phospho-JNK, p38 and phospho-p38, and Src were purchased from Cell Signaling (Beverly, MA).

Immunohistochemistry. Paraffin-embedded specimens were cut into 5 µm sections, then baked at 65°C for 30 minutes. H&E preparations of each specimen were done to confirm the presence of nonnecrotic tumor. The paraffin was removed by incubation in xylene, followed by graded alcohols. Immunostaining was done with the DAKO Envision peroxidase rabbit ready-to-use system. The slides were sequentially incubated at room temperature as follows: (a) in DAKO antigen block reagent to block nonspecific antibody binding; (b) with the specific primary antibody for 1 hour; (c) with the DAKO secondary antibody to rabbit for 30 minutes; and (d) developed with DAKO diaminobenzidine solution. The tissues were then stained with Gill's hematoxylin, dehydrated through graded alcohols, and mounted. For EG-1 studies, we used antigen retrieval with 0.01 mol/L sodium citrate (pH 6.0) in a 95°C water bath for 20 minutes. The EG-1 antiserum was used at 1:400 dilution, and EG-1 affinity-purified polyclonal antibodies at 1:2,000. The negative control was preimmune rabbit serum at 1:400 dilution. The histologic slides were reviewed by a Board-certified pathologist (J.Y.R.). Photography was carried out with a Leica DMLS microscope (McBain Instruments, Chatsworth, CA) and a Nikon CoolPix 995 digital camera (Tokyo, Japan).

Western blot analysis. Cell pellets were lysed in preheated 0.025 mol/L Tris (pH 7.4), 0.001 mol/L EDTA, and 0.3% SDS, and then boiled for 5 minutes. The cell lysate was centrifuged at 12,000 x g for 10 minutes, and the supernatant was saved. Protein concentration was measured by the Bradford assay (Bio-Rad, Hercules, CA). For Western blot analysis, ~40 µg of protein were separated by a 12% SDS-PAGE gel, and transferred to a nitrocellulose membrane by electrophoretic blotting. The membrane was blocked overnight (4°C) with 5% nonfat dry milk in TBS-0.1% Tween 20, and then incubated with a 1:500 dilution of EG-1 antiserum for 2 hours. The blots were then washed thrice over 30 minutes in TBS-Tween 20, and incubated for 1 hour with horseradish peroxidase–conjugated secondary antibody goat anti-rabbit IgG (1:10,000), and then washed in TBS-Tween 20 as before. The membranes were then developed using the Supersignal West Pico Chemiluminescent Western blotting detection system according to the instructions of the manufacturer (Pierce, Arlington Heights, IL).

Immunoprecipitation. Cell lysates were preincubated solely with protein A/G Plus-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C for 1 hour, and the mixture was centrifuged at 3,000 x g for 5 minutes to pellet these beads and any nonspecific interacting proteins. One milligram of supernatant protein was incubated with anti–EG-1 antibody and 30 µL of protein A/G Plus-Agarose overnight at 4°C under agitation, and 1 mg of proteins from the same source was incubated with normal rabbit IgG (Santa Cruz Biotechnology) and protein A/G Plus-Agarose (for negative controls). After incubation, immunocomplexes were pelleted by centrifugation at 3,000 x g for 5 minutes at 4°C. The pellets were then resuspended and washed three additional times with immunoprecipitation buffer to remove nonspecific interactions. Laemmli loading buffer was then added to the beads. After boiling, the proteins were separated by 12% SDS-PAGE and analyzed by Western blot.

Size exclusion chromatography-mass spectrometry. Anti-FLAG M2 affinity gel (Sigma) was used to purify recombinant FLAG-tagged EG-1 peptide from transiently transfected HEK-293 cells, following the protocol of the manufacturer. Briefly, cell lysates were collected and loaded onto the column under gravity flow. The column was washed and then eluted with seven 1-mL aliquots of 0.1 mol/L glycine-HCl at pH 3.5 into vials containing 25 µL of 1 mol/L Tris (pH 8.0). The vial with the highest concentration of the EG-1 protein (vial 2) was subjected to mass spectrometry (MS).

The protocol of Whitelegge et al. (18) was used to separate the EG-1 from salt by size exclusion chromatography before analysis in the mass spectrometer (size exclusion chromatography-MS). Approximately 10 µg of EG-1 suspended in 0.1 mol/L glycine-HCl at pH 7.0 were dried down in vacuo (SpeedVac) and then resuspended in 100 µL of 90% formic acid immediately before size exclusion chromatography-MS. The size exclusion chromatography was done using a mobile phase of CHCl3/methanol/1% aqueous formic acid (4:4:1, v/v/v) and a Super SW 2000 column (4.6 x 300 mm, Tosoh Bioscience, Montgomeryville, PA) at 250 µL/min and 40°C. Before delivery to the electrospray-ionization source, the column effluent was monitored with a UV detector (280 nm). Electrospray ionization MS was done using a triple quadrupole instrument (API III, Applied Biosystems) tuned and calibrated as described (19). Data were processed using MacSpec 3.3, Hypermass, and BioMultiview 1.3.1 software (Applied Biosystems).

Microliquid chromatography with tandem mass spectrometry. After the EG-1 peptides were eluted from the FLAG column, we confirmed the presence and purity of EG-1 by Western blotting. Then the sample was subjected to 12% SDS-PAGE, and the gel was stained by SYPRO Ruby Protein Gel Stain (Molecular Probes, Eugene, OR) following the manual from the manufacturer. Subsequently, the EG-1 bands were excised and dehydrated in acetonitrile for 30 minutes, and dried completely by SpeedVac. DTT (10 mmol/L) dissolved in 100 mmol/L NH4HCO3 was added to the sample, which was then incubated for 1 hour at 56°C. The liquid was removed, and 55 mmol/L iodoacetamide dissolved in 100 mmol/L NH4HCO3 was added for 45 minutes at room temperature in the dark. The sample was washed in 100 mmol/L NH4HCO3 for 10 minutes, dehydrated in acetonitrile for 30 minutes, followed by swelling in 100 mmol/L NH4HCO3 for 30 minutes, dehydrated again in acetonitrile for 30 minutes, and finally dried completely by SpeedVac. Then, the sample was digested in trypsin solution (50 mmol/L NH4HCO3, 5 mmol/L CaCl2, 12.5 ng/µL trypsin) on ice for 45 minutes. The liquid was then removed, and the sample incubated in the same solution without trypsin at 37°C overnight. On the following day, the sample was washed with 20 mmol/L NH4HCO3; then the extraction of the EG-1 peptides was carried out with 5% formic acid and 50% acetonitrile for 20 minutes, and repeated twice. The sample was extracted once with acetonitrile for 20 minutes. All the postigestion extractions were pooled together and dried down by SpeedVac.

Samples were analyzed by microliquid chromatography with tandem mass spectrometry (micro-LC-MS/MS) with data-dependent acquisition (LCQ-DECA, ThermoFinnigan, San Jose, CA) after dissolution in 5 µL of 70% acetic acid (v/v). A reverse-phase column (200 µm x 10 cm; PLRP/S 5 µm, 300 Å; Michrom Biosciences, San Jose, CA) was equilibrated for 10 minutes at 1.5 µL/min with 95% A, 5% B (A, 0.1 % formic acid in water; B, 0.1% formic acid in acetonitrile) before sample injection. A linear gradient was initiated 10 minutes after sample injection ramping to 60% A, 40% B after 50 minutes and 20% A, 80% B after 65 minutes. Column eluent was directed to a coated glass electrospray emitter (TaperTip, TT150-50-50-CE-5, New Objective) at 3.3 kV for ionization without nebulizer gas. The mass spectrometer was operated in "triple-play" mode with a survey scan (m/z 400-1,500), data-dependent zoom scan and MS/MS. Individual sequencing experiments were matched to a custom protein sequence database using Sequest software (ThermoFinnigan).

Statistical analysis. Descriptive statistics, such as mean and SE, were used to summarize the results. The ANOVA test was done for comparison among the various groups followed by the Bonferroni posttest. The Student's t test was used for comparison between only two groups. Statistical significance is defined by P < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The EG-1 gene and peptide. A BLASTN search for sequence homology done in the GenBank database revealed that EG-1 has no significant homology to any gene with a known function. The homology of the human EG-1 peptide to its mouse counterpart is 94.9%, and 95.5% to its rat counterpart. The homology between mouse and rat EG-1 is 98.9%. A Profile Scan search revealed a proline-rich region in the NH2 terminus (Fig. 1A and B). Of interest, we have found similar sequences to EG-1 in several insects, but these seem to lack the NH2-terminal polyproline region.



View larger version (33K):
[in this window]
[in a new window]
  		Figure 1. A, EG-1 exons and introns with the NH2-terminal polyproline region. B, alignment of deduced amino acid sequence of human EG-1 with its murine and rat homologues. Amino acid differences in the sequence are indicated by rectangular boxes. C, Western blot analysis with anti–EG-1 antibody showing EG-1 expression in cell lysates from HEK-293 cells transiently transfected with full-length EG-1/FLAG tag. D, Western blot analysis with anti–EG-1 antibody showing the FLAG-tagged EG-1 peptide which was purified by elution from an anti-FLAG affinity gel. E, a zero charge deconvoluted electrospray ionization mass spectra of EG-1. The measured mass of 21,218.0 Da is consistent with a monoacetylated form of the protein.

 
Western blot analysis showed that the transfected full-length EG-1/FLAG exists primarily as a 22 kDa protein, with possible degradation peptide products (Fig. 1C and D). It should be noted that our transfectant EG-1 product contains at the NH2 terminus 15 additional amino acids containing the FLAG tag (MDYKDDDDKNSAGSN). Based on amino acid sequence alone, the calculated masses of EG-1 alone and EG-1/FLAG tag transfectant are 19,520.2 and 21,176.8 Da, respectively.

To confirm the size of the EG-1/FLAG tag transfectant product, we did size exclusion chromatography-MS. Figure 1D shows the zero charge deconvoluted electrospray ionization mass spectra of EG-1. The measured mass of 21,218.0 Da is within 0.01% of that calculated for a monoacetylated (M ± 42 Da) form of EG-1 (21,218.8 Da; average mass) based on analysis using the ExPASy Proteomics Server (Swiss Institute of Bioinformatics).

Micro-LC-MS/MS was done so that peptides generated from a tryptic digest of the FLAG Tag EG-1 peptide could be searched against the protein sequence database using Sequest (ThermoFinnigan). Peptides uniquely matching the EG-1 sequence are shown in Table 1. No significant matches with proteins other than EG-1 were found.


View this table:
[in this window]
[in a new window]
  		Table 1. EG-1 peptides identified by MS/MS

 
Overexpression of EG-1 stimulates HEK-293 proliferation. We transfected a full-length cDNA of EG-1 carrying a FLAG tag into HEK-293 cells (these cells do have a low level of endogenous EG-1). Successfully stable clones of transfected cells were confirmed to have increased EG-1 expression by Northern blot analyses (data not shown). Subsequent experiments showed that the EG-1–transfected cells have increased proliferation [28,092 ± 950 counts per minute (cpm)] in comparison with the ones transfected with empty vectors (16,546 ± 462 cpm, P < 0.001) as well as with the wild-type cells (16,608 ± 627 cpm, P < 0.001; Fig. 2A). Figure 2B shows the corresponding levels of EG-1 peptide in these cells. One milligram of cell lysates was immunoprecipitated with anti–EG-1 antibody, and then immunoblotted also with anti–EG-1 antibody. EG-1 stably transfected cells contain ~3-fold as much of the 22 kDa EG-1/FLAG peptide, in comparison with empty vector–transfected cells.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 2. A, proliferation of HEK-293 cells. Lane 1, wild-type; lane 2, permanent clone of HEK-293 cells transfected with empty vector; lane 3, permanent clone of HEK-293 cells transfected with EG-1. Columns, mean expressed in counts per minute; bars, SE. P < 0.001. B, one milligram of the above cell lysate proteins was immunoprecipitated with anti–EG-1 antibody overnight, then immunoblotted with the same antibody. C, proliferation of HEK-293 cells transfected with EG-1. Lane 1, cotransfected with empty vector; lane 2, cotransfected with siRNA1; lane 3, cotransfected with siRNA2; lane 4, cotransfected with siRNA3. Columns, mean expressed in counts per minute; bars, SE. P < 0.001. D, Western blot analysis of EG-1 expression of the above cell lysates.

 
Suppression of EG-1 inhibits cellular proliferation. We designed multiple plasmids carrying different siRNAs to the EG-1 sequence. These siRNAs were cotransfected with a full-length cDNA of EG-1/FLAG into HEK-293 cells. The proliferation results are as follows: 34,847 ± 2,060 cpm in vector-transfected cells; 26,892 ± 801 cpm in cells transfected with siRNA1; 25,785 ± 970 cpm in cells transfected with siRNA2; and 12,548 ± 12 cpm in cells transfected with siRNA3 (Fig. 2C). ANOVA analysis shows that the inhibitory effect exerted by siRNA3 is significant in comparison with that by vector alone (P < 0.001). Whole-cell lysates were collected 24 hours after transfection, subjected to SDS-PAGE, then immunoblotted with anti–EG-1 antibody. This analysis showed minimal levels of EG-1 peptide in cells cotransfected with siRNA3 (Fig. 2D).

Overexpression of EG-1 stimulates breast cancer cell proliferation. We transiently transfected a full-length cDNA of EG-1 carrying a FLAG tag into the human breast cancer cell lines MCF-7 and MDA-MB-231. Subsequent experiments showed that the EG-1–transfected MCF-7 cells have increased proliferation (9,613 ± 694 cpm) in comparison with the ones transfected with empty vectors (7,213 ± 252 cpm). Cotransfection with EG-1 and siRNA3 abrogated the increased proliferation (5,947 ± 264 cpm, P = 0.0002; Fig. 3A). The same phenomenon was observed with MDA-MB-231 cells transfected with empty vector (34,651 ± 3,756 cpm), with EG-1 (61,605 ± 2,288 cpm), and with EG-1 and siRNA3 combination (34,197 ± 429 cpm, P < 0.0001; Fig. 3C). Figure 3B and D shows the corresponding levels of EG-1 peptide in these cells, as shown with Western blot analysis of cell lysates.



View larger version (26K):
[in this window]
[in a new window]
  		Figure 3. Proliferation of MCF-7 (A) and MDA-MB-231 (C) human breast cancer cells. Lane 1, cells transfected with empty vector; lane 2, cells transfected with EG-1; lane 3, cells transfected with both EG-1 and siRNA3. Columns, mean expressed in counts per minute; bars, SE. P < 0.001. Western blot analysis of EG-1 expression of the above cell lysates compared with purified EG-1 peptide positive control. B, MCF-7; D, MDA-MB-231.

 
EG-1 overexpression increases the tumorigenicity of mouse xenografts. We next examined the effect of EG-1 on the tumorigenicity of permanently transfected and wild-type HEK-293 cells in SCID mice. One group of mice was injected s.c. in the flank with wild-type HEK-293 cells, a second group with a stably transfected empty vector clone, and the third group with one EG-1–overexpressing clone. There were four mice per group. At day 30, the xenograft tumor sizes are as follows: 1,204 ± 384 mm3 in the wild-type group, 899 ± 313 mm3 in the empty vector group, and 1,956 ± 441 mm3 in the EG-1 vector group (Fig. 4A). ANOVA analysis shows that the stimulatory effect exerted by EG-1 transfection in the xenografts is significant in comparison with that by vector alone (P < 0.01) as well as with that by wild-type (P < 0.05). This phenomenon was similarly observed in other xenograft experiments using other stable clones generated in our laboratory (Fig. 4C; P < 0.0001).



View larger version (27K):
[in this window]
[in a new window]
  		Figure 4. The tumorigenicity of different HEK-293 clones. Cells were injected s.c. into mice, and tumor size measured in three dimensions with calipers and expressed as volume. Columns, mean; bars, SE. A, 4 x 107 wild-type cells (white columns), and a clone of HEK-293 cells stably transfected with empty vector (diagonal lines) or with EG-1 (black columns); n = 4, P < 0.01. B, immunohistochemistry of mouse xenografts from empty vector versus EG-1 stable clones, with positive staining for EG-1 in brown. C, 5 x 107 cells of other clones of HEK-293 stably transfected with empty vector ({diamondsuit}) or with EG-1 ({04-4016fx01l}); n = 8, P < 0.0001.

 
To examine the expression of the EG-1 product in mouse tumors, multiple xenograft samples were analyzed by immunohistochemistry using the anti–EG-1 antibody. The histologic slides were reviewed by a Board-certified pathologist (J.Y.R). Figure 4B shows a representative slide prepared from a vector-transfected tumor, and a slide from an EG-1–transfected tumor. The EG-1–transfected xenografts seem to express a higher amount of the EG-1 peptide, in comparison with those transfected with empty vector.

EG-1 overexpression influences certain kinase pathways. Western blot analysis of cell lysates showed that the phosphorylated p44/42 MAP kinase level is elevated in EG-1–transfected HEK-293 cells in comparison with those transfected with empty vector (Fig. 5A). The phosphorylated forms of the JNK (Fig. 5B) and the p38 kinase (Fig. 5C) are similarly increased in EG-1–overexpressing cells. Of note, we also observed similar changes in phospho-JNK levels in MCF-7 cell experiments, and in p44/42 MAPK levels in MDA-MB-231 cell experiments (data not shown). We further investigated the proliferation of EG-1–transfected HEK-293 cells when treated with the following MAPK inhibitors: PD98059 (inhibits MAPK), SB203580 (inhibits p38), and U0126 (inhibits MAP/extracellular signal-regulated kinase (ERK) kinase 1 and 2). These inhibitors significantly block the increase of proliferation by EG-1 overexpression in HEK-293 cells (Fig. 5D; P < 0.05).



View larger version (29K):
[in this window]
[in a new window]
  		Figure 5. Western blot analysis of kinase expression in HEK-293 cell lysates. Equivalent amounts of protein were loaded per lane. Lane 1, permanent clone of HEK-293 cells transfected with empty vector; lane 2, permanent clone of HEK-293 cells transfected with EG-1. Expression of phosphorylated versus nonphosphorylated p44/42 MAP kinase (A), JNK (B), and p38 kinase (C). D, MAPK inhibitors block the increase of proliferation by EG-1 overexpression in HEK-293 cells. Columns, mean expressed in counts per minute; bars, SE. Cells were wild type (WT), transfected with empty vector (EV), or transfected with EG-1 (NT), P = 0.015. In the group with EG-1 transfection, cells were either not treated (NT), or treated with vehicle (DMSO) or MAPK inhibitors (PD98059, SB203580, and U0126; 10 µmol/L), P < 0.05.

 
EG-1 and c-Src form a protein complex. In other experiments, we found that EG-1 recombinant peptides bind to the Src homology 3 domain of c-Src by Domain Array assays (data not shown). We thus asked if EG-1 and c-Src can also have protein-protein interaction inside living mammalian cells. We transiently transfected HEK-293 cells with either empty vector or with EG-1 plasmid, and prepared cell lysates. We then immunoprecipitated c-Src with anti–c-Src antibody, followed by Western blotting using the anti–EG-1 antibody, and discovered that EG-1 does indeed bind to c-Src (Fig. 6).



View larger version (16K):
[in this window]
[in a new window]
  		Figure 6. Western blot analysis of EG-1 expression in HEK-293 cell lysates. Lane 1, cells transiently transfected with empty vector; lanes 2 to 4, cells transiently transfected with EG-1. Equivalent amounts of cell lysate proteins were immunoprecipitated with an anti-Src antibody (lanes 1 and 2). Lane 3, negative control, in which normal mouse antibody was used to immunoprecipitate an equivalent amount of the same cell lysate of transiently EG-1–transfected HEK-293. Lane 4, positive control, in which an equivalent amount of the same cell lysate was immunoprecipitated with anti–EG-1 antibody. Subsequently, all lanes were blotted with anti–EG-1 antibody.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We report here that the novel gene EG-1 can stimulate cellular proliferation. Overexpression of EG-1 in transfected cells resulted in a marked increase of in vitro proliferation. On the other hand, siRNA cotransfection resulted in inhibition of proliferation. In vivo, mouse xenograft models showed that EG-1 transfectants had a growth advantage as evidenced by the formation of larger s.c. tumors. Because cellular proliferation is an important component of the malignant phenotype, the current observations are consistent with our previous reports on the expression profile of this novel gene. We have shown in our first publication that the expression of EG-1 is significantly elevated in cancerous compared with benign epithelial cells, as seen in Northern blot analyses (16). Subsequent immunohistochemical studies of several human pathologic specimens confirmed our hypothesis that EG-1 is associated with the malignant phenotype of the common epithelial-derived cancers of the breast, colon, and prostate (17).

Our present observations are unique in part because EG-1 is a novel gene with completely unknown function, which was discovered in our laboratory 2 years ago. The fact that this gene is highly conserved in mammals suggests that it may serve an important and fundamental role in cellular biology. The EG-1 protein product is unique because we could not find any homology of its tryptic peptides with any known proteins in the database. Thus, the major finding is that a unique and novel gene is a positive signal for cellular proliferation. The extent of proliferation correlates with the levels of EG-1 peptide, as seen in Western blot analyses in vitro and immunohistochemistry in vivo. As further evidence for the stimulatory effect of EG-1, we showed that the knockdown of EG-1 expression by specifically designed siRNAs resulted in inhibition of cellular proliferation.

To investigate possible mechanisms for the stimulatory activity of EG-1, we analyzed the well-known MAPK family kinase signaling pathway which has been shown to be crucial in promoting cellular proliferation (20). We used the stable clones that overexpress EG-1, and compared their MAPK activity with that expressed by stable clones carrying only empty vectors. By Western blot analysis, we found that EG-1 overexpression was correlated with activation of the following MAP kinases: ERK-1 and -2, JNK, and p38. Further work is needed to study the network involved in this interaction, and to determine whether the MAPK pathway really plays a role in EG-1–associated cellular proliferation.

A key to the understanding of cellular signal transduction pathways is to determine whether certain proteins of interest interact with one another. Protein-protein interactions are often mediated by noncatalytic and conserved domains (21). To further clarify the function of EG-1, we analyzed the sequence of this highly conserved gene. EG-1 has two tyrosines at positions 68 and 163. The presence of an NH2-terminal polyproline region suggests that EG-1 may interact with Src homology 3 domains. This led us to screen more than 100 proteins with Src homology 3 domains by domain array assays, in which we repeatedly observed an association between EG-1 and c-Src (data not shown). Immunoprecipitation with anti-Src antibody, followed by immunoblotting with anti–EG-1 antibody, showed an interaction between these two molecules. c-Src is a member of the Src family of cytoplasmic tyrosine kinases that regulate cell growth, differentiation, cell shape, migration, and survival (22). c-Src has been reported to be overexpressed and to play a role in human carcinomas of the breast, colon, and others (23). Src family tyrosine kinases are often activated by receptor tyrosine kinases, such as epidermal growth factor receptor or platelet-derived growth factor receptor (24). Further work is needed to elucidate the effects of the observed association between Src and EG-1.

The above observations collectively support the hypothesis that the novel gene EG-1 is a positive stimulator of cellular proliferation. Because cellular proliferation is an important component of the malignant phenotype, our present findings suggest that EG-1 may be an important target in the design of novel cancer therapies. In addition, we have now shown that EG-1 overexpression is potentially associated with the well-known MAP kinase family signaling pathway, which could underline the mechanism of the function of EG-1. Finally, we have observed that EG-1 forms protein-protein complexes with the Src tyrosine kinase, which is critical in the regulation of cell growth, differentiation, migration, and survival. The cross-talk between MAPK family and c-Src has been reported by several groups (25, 26). When c-Src is catalytically active, it is presumed to phosphorylate epidermal growth factor receptor (EGFR) monomers on tyrosine residues leading to EGFR transactivation. Tyrosine-phosphorylated EGFR forms complex with adapter proteins, including growth factor receptor binding protein 2-Sos, which activate Ras and the ERK pathway (27).

We think that these results will form the basis for further studies of this interesting gene, and the possible translation of the discovery of this molecule into potential use in cancer diagnosis and/or treatment.


   Acknowledgments
 
Grant support: DOD 17-02-1-0330 and the California Cancer Research Committee. R.S. Maul was supported by the Komen Foundation, and M.R. Sartippour by the American Cancer Society.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Timothy Lane for his assistance. J. Whitelegge wishes to thank the Pasarow and Keck foundations for mass spectrometry equipment funding.


   Footnotes
 
Note: M. Lu and L. Zhang contributed equally to the work.

Received 11/ 9/04. Revised 5/ 6/05. Accepted 5/12/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Dickson RB, Lippman ME. Cancer of the breast: molecular biology of breast cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven; 2000. p. 1633–51.
  2. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593–603.[Free Full Text]
  3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757–63.[Free Full Text]
  4. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.[Abstract]
  5. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356–61.[Abstract/Free Full Text]
  6. Nguyen M. Angiogenic factors as tumor markers. Invest New Drugs 1997;15:29–37.[CrossRef][Medline]
  7. Liu Y, Wang JL, Chang H, Barsky SH, Nguyen M. Breast cancer diagnosis with nipple fluid bFGF. Lancet 2000;356:567.[CrossRef][Medline]
  8. Lee MC, Tomlinson J, Nguyen M. Lessons from clinical trials of anti-angiogenic drugs in the treatment of cancer. In: Mousa SA, editor. Therapeutic implications of angiogenesis inhibitors and stimulators: Current status and future treatment directions. Texas: Landes Bioscience; 2000. p. 151–60.
  9. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–5.[Abstract/Free Full Text]
  10. Nguyen M, Strubel N, Bischoff J. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 1993;365:267–9.[CrossRef][Medline]
  11. Nguyen M, Corless CL, Kraling BM, et al. Vascular expression of E-selectin is increased in estrogen receptor negative breast cancer: a role for tumor cell-secreted IL-1{alpha}. Am J Path 1997;150:1307–14.[Abstract]
  12. Diatchenko L, Lau YC, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci 1996;93:6025–30.[Abstract/Free Full Text]
  13. Nguyen M, Lee MC, Wang JL, et al. The human myoepithelial cell expresses a multifaceted anti-angiogenic phenotype. Oncogene 2000;19:3449–59.[CrossRef][Medline]
  14. Wang JL, Liu Y, Lee MC, et al. Identification of tumor angiogenesis-related genes by subtractive hybridization. Microvasc Res 2000;59:394–7.[CrossRef][Medline]
  15. Liu C, Shao ZM, Zhang L, et al. Human endomucin is an endothelial marker. Biochem Biophys Res Commun 2001;288:129–36.[CrossRef][Medline]
  16. Liu C, Zhang L, Beatty P, et al. Identification of a novel endothelial-derived gene. Biochem Biophys Res Commun 2002;290:602–12.[CrossRef][Medline]
  17. Zhang L, Maul RS, Rao J, et al. Expression pattern of the novel gene EG-1 in cancer. Clin Cancer Res 2004;10:3504–8.[Abstract/Free Full Text]
  18. Whitelegge JP, Le Coutre J, Lee JC, Prive GG, Faull KF, Kaback HR. Towards the bilayer proteome, electrospray-ionization mass spectrometery of large intact transmembrane proteins. Proc Natl Acad Sci 1999;96:10695–8.[Abstract/Free Full Text]
  19. Whitelegge JP, Gundersen CB, Faull KF. Electrospray-ionization mass spectrometry of intact intrinsic membrane proteins. Protein Sci 1998;7:1423–30.[Abstract]
  20. Johnson GL, Lapadat R. Mitogen activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911–2.[Abstract/Free Full Text]
  21. Pawson T. Protein modules and signalling networks. Nature 1995;373:573–80.[CrossRef][Medline]
  22. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene 2004;23:7906–9.[CrossRef][Medline]
  23. Ishizawar RC, Tice DA, Karaoli T, Parsons SJ. The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism. J Biol Chem 2004;279:23773–81.[Abstract/Free Full Text]
  24. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004;23:7957–68.[CrossRef][Medline]
  25. Levi NL, Hanoch T, Benard O, et al. Stimulation of Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary {alpha} T3-1 cell line is mediated by protein kinase C, c-Src, and CDC42. Mol Endocrinol 1998;12:815–24.[Abstract/Free Full Text]
  26. Gupta SK, Gallego C, Johnson GL, Heasley LE. MAP kinase is constitutively activated in gip2 and src transformed rat 1a fibroblasts. J Biol Chem 1992;267:7987–90.[Abstract/Free Full Text]
  27. Daaka Y. Mitogenic action of LPA in prostate. Biochim Biophys Acta 2002;1582:265–9.[Medline]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
K. S. Beyer, R. L. Beauchamp, M.-F. Lee, J. F. Gusella, A. M. Naar, and V. Ramesh
Mediator Subunit MED28 (Magicin) Is a Repressor of Smooth Muscle Cell Differentiation
J. Biol. Chem., November 2, 2007; 282(44): 32152 - 32157.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, M.
Right arrow Articles by Brooks, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, M.
Right arrow Articles by Brooks, M. N.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online